Capsicure

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Capsicure sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).

3 total trials 3 currently recruiting upper quartile by trial count

Capsicure: 3 sponsored US clinical trials, 3 recruiting.

Capsicure sponsors 3 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting. The most-studied condition in this pipeline is Diabetic Foot Ulcer, with 2 trials.

Upper-quartile sponsor footprint

Capsicure sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

3 total, page 1 of 1

RECRUITING NA

CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations

NCT07046767
RECRUITING NA

Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06455475
RECRUITING NA

Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone

NCT06572839

Therapeutic Areas

Diabetic Foot Ulcer 2
Venous Leg Ulcer 1
Wound; Foot 1
Diabetic Foot Ulcer (DFU) 1

What is open in the Capsicure pipeline

3 recruiting of 3 indexed (100% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Diabetic Foot Ulcer (2 trials), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Capsicure: open-pipeline peers nationwide

Peers matched on 3 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Capsicure sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%50%100%150% Total trials Recruiting share Capsicure10xBio22nd Century GroupAA SecordAAADRS Clinical Research CenterAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Capsicure sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Capsicure sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 3 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Capsicure page

3 registered trials is a research-attention snapshot, not an endorsement of Capsicure or any single study.

  • 3 of Capsicure's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diabetic Foot Ulcer is the condition Capsicure studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Foot Ulcer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Capsicure pipeline card: 3 registered trials from official public datasets.Report a data error.